Sage Theraputics Shares Plunge After Depression Drug Fails Late-Stage Trial

Sage Theraputics shares plunge after depression drug fails late-stage trial

CNBC Television

Sage Therapeutics slumps, Biogen bounces

CNBC Television

Sage Therapeutics CEO on why its moving to treat depression next

CNBC Television

Sage CEO Jeff Jonas on depression drug development

CNBC Television

Sage Therapeutics shares soar after postpartum depression drug meets main goal

Sage Therapeutics CEO: Treating Postpartum Depression | Mad Money | CNBC

CNBC Television

FDA approves first postpartum depression pill from Biogen, Sage

Sage Targets June Launch as FDA Approves Postpartum Drug

Bloomberg Television

056 - Major Depressive Disorder Sees Major Interest from Biotechs

Breaking Biotech

Sage's depression drugs reach the main goal of the later study.

Stock Watch Tonight

Sage/Biogen Announce Positive Results in Ph. 3 CORAL Depression Drug Trial

HPR

How a Clinical Trial for an Antidepressant Works | Shkreli Analyses Sage Therapeutics (SAGE) stock

The Shkreli Pill

Sage's depression drugs improve symptoms, but concerns about durability weigh on share prices

Stock Watch Tonight

Recovering from Setbacks, Sage Therapeutics to Develop Treatment for PPD & Major Depressive Disorder

Why Antidepressants Make You Feel Worse - At First

Dr. Tracey Marks

DisappEAR by PAVmed

Episodic drugs provide hope for depression sufferers

CNBC Television

How quickly do antidepressants work? #shorts

Dr. Tracey Marks

Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling ...

What Is Happening With The Stock SAGE THERAPEUTICS (Stock Breakdown)